# Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

> **NCT00972335** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 18 (actual)

## Conditions studied

- Intracranial Meningioma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00972335
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study terminated early due to slow accrual
- **Last updated:** 2021-11-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972335, "Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00972335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*